$17.3 Billion is the total value of Baker Brothers Advisors's 107 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 17.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SGEN | Sell | Seagen Inc. | $8,574,894,019 | -9.7% | 44,554,162 | -5.0% | 49.62% | -4.0% |
| INCY | Buy | Incyte Corporation | $2,252,083,986 | -13.9% | 36,178,056 | +0.0% | 13.03% | -8.4% |
| BGNE | BeiGene, Ltd.sponsored adr | $2,080,564,335 | -17.3% | 11,668,897 | 0.0% | 12.04% | -12.0% | |
| ACAD | Buy | ACADIA Pharmaceuticals Inc. | $1,026,607,457 | +30.1% | 42,864,612 | +2.2% | 5.94% | +38.4% |
| MDGL | Madrigal Pharmaceuticals, Inc. | $356,921,103 | -4.6% | 1,545,113 | 0.0% | 2.07% | +1.4% | |
| BMRN | BioMarin Pharmaceutical Inc. | $330,272,297 | -10.9% | 3,810,248 | 0.0% | 1.91% | -5.2% | |
| IMCR | Immunocore Holdings plcads | $151,143,031 | +21.3% | 2,520,731 | 0.0% | 0.88% | +29.1% | |
| New | Invitae Corporationnote 1.5% 4/1/2028 | $135,000,000 | – | 300,000,000 | +100.0% | 0.78% | – | |
| KOD | Kodiak Sciences Inc. | $119,442,381 | +11.3% | 17,310,490 | 0.0% | 0.69% | +18.3% | |
| AKRO | Akero Therapeutics, Inc. | $110,579,569 | +22.0% | 2,368,378 | 0.0% | 0.64% | +29.8% | |
| ARGX | argenx SEsponsored adr | $109,186,367 | +4.6% | 280,159 | 0.0% | 0.63% | +11.3% | |
| RYTM | Rhythm Pharmaceuticals, Inc. | $107,156,423 | -7.6% | 6,498,267 | 0.0% | 0.62% | -1.7% | |
| REPL | Replimune Group, Inc. | $106,307,662 | +31.5% | 4,578,280 | 0.0% | 0.62% | +39.8% | |
| ABCL | Buy | AbCellera Biologics Inc. | $106,268,163 | +34.9% | 16,450,180 | +57.4% | 0.62% | +43.4% |
| KYMR | Buy | Kymera Therapeutics, Inc. | $100,589,067 | +17.9% | 4,375,340 | +51.9% | 0.58% | +25.4% |
| Buy | Roivant Sciences Ltd. | $95,040,207 | +169.6% | 9,428,592 | +97.4% | 0.55% | +186.5% | |
| BCRX | BioCryst Pharmaceuticals, Inc. | $89,484,159 | -15.6% | 12,710,818 | 0.0% | 0.52% | -10.2% | |
| SWTX | Buy | SpringWorks Therapeutics, Inc. | $78,655,962 | +11.0% | 2,999,846 | +8.9% | 0.46% | +17.9% |
| Entrada Therapeutics, Inc. | $73,668,500 | +4.4% | 4,865,819 | 0.0% | 0.43% | +10.9% | ||
| RVMD | Revolution Medicines, Inc. | $71,997,438 | +23.5% | 2,691,493 | 0.0% | 0.42% | +31.5% | |
| IMTX | Buy | Immatics N.V. | $65,095,017 | +81.9% | 5,640,816 | +8.7% | 0.38% | +93.3% |
| KDNY | Chinook Therapeutics, Inc. | $55,908,861 | +66.0% | 1,455,202 | 0.0% | 0.32% | +77.0% | |
| MRTX | Mirati Therapeutics, Inc. | $50,935,496 | -2.8% | 1,409,784 | 0.0% | 0.30% | +3.5% | |
| DICE Therapeutics, Inc. | $48,122,618 | +62.2% | 1,035,786 | 0.0% | 0.28% | +72.7% | ||
| BMEA | Biomea Fusion, Inc. | $46,291,431 | -29.2% | 2,108,949 | 0.0% | 0.27% | -24.7% | |
| PRLD | Prelude Therapeutics Inc. | $45,557,208 | -21.1% | 10,123,824 | 0.0% | 0.26% | -15.9% | |
| DNLI | Buy | Denali Therapeutics Inc. | $42,946,552 | +71.2% | 1,455,322 | +33.7% | 0.25% | +83.1% |
| CERS | Cerus Corporation | $39,526,193 | -17.2% | 16,067,558 | 0.0% | 0.23% | -11.9% | |
| KNSA | Buy | Kiniksa Pharmaceuticals, Ltd. | $39,558,844 | +31.3% | 2,809,577 | +0.4% | 0.23% | +39.6% |
| NRIX | Nurix Therapeutics, Inc. | $38,782,429 | +12.5% | 3,882,125 | 0.0% | 0.22% | +19.1% | |
| RARE | Buy | Ultragenyx Pharmaceutical Inc. | $36,122,512 | +91.3% | 783,059 | +66.3% | 0.21% | +102.9% |
| AVTE | Aerovate Therapeutics, Inc. | $33,673,665 | -15.0% | 1,963,479 | 0.0% | 0.20% | -9.3% | |
| IGMS | Buy | IGM Biosciences, Inc. | $29,141,048 | -32.8% | 3,157,210 | +0.0% | 0.17% | -28.4% |
| XENE | Xenon Pharmaceuticals Inc. | $28,938,102 | +7.6% | 751,639 | 0.0% | 0.17% | +14.4% | |
| IMGN | New | ImmunoGen, Inc. | $28,684,230 | – | 1,520,097 | +100.0% | 0.17% | – |
| DBVT | DBV Technologies S.A.sponsored adr | $27,767,102 | +12.4% | 14,614,264 | 0.0% | 0.16% | +20.1% | |
| VERV | Verve Therapeutics, Inc. | $26,559,938 | +30.0% | 1,416,530 | 0.0% | 0.15% | +38.7% | |
| 2seventy bio, Inc. | $25,274,963 | -0.8% | 2,497,526 | 0.0% | 0.15% | +5.0% | ||
| IDYA | Buy | IDEAYA Biosciences, Inc. | $24,959,891 | +118.3% | 1,062,123 | +27.5% | 0.14% | +132.3% |
| STOK | Buy | Stoke Therapeutics, Inc. | $22,644,430 | +28.5% | 2,130,238 | +0.7% | 0.13% | +36.5% |
| BCYC | Bicycle Therapeutics plcsponsored ads | $21,534,133 | +20.0% | 843,814 | 0.0% | 0.12% | +27.6% | |
| GLUE | Buy | Monte Rosa Therapeutics, Inc. | $20,714,064 | +608.9% | 3,023,951 | +706.2% | 0.12% | +650.0% |
| CABA | Buy | Cabaletta Bio, Inc. | $20,578,540 | +85.1% | 1,594,000 | +18.6% | 0.12% | +98.3% |
| KRYS | Sell | Krystal Biotech, Inc. | $19,950,252 | -17.7% | 169,934 | -43.9% | 0.12% | -12.9% |
| SMMT | Summit Therapeutics Inc. | $15,824,810 | +43.4% | 6,304,705 | 0.0% | 0.09% | +53.3% | |
| ANAB | AnaptysBio, Inc. | $15,782,294 | -6.5% | 775,924 | 0.0% | 0.09% | -1.1% | |
| Prime Medicine, Inc. | $15,067,027 | +19.1% | 1,028,466 | 0.0% | 0.09% | +26.1% | ||
| PACB | Pacific Biosciences of California, Inc. | $14,999,501 | +14.9% | 1,127,782 | 0.0% | 0.09% | +22.5% | |
| RLAY | Buy | Relay Therapeutics, Inc. | $14,571,070 | +211.5% | 1,160,117 | +308.5% | 0.08% | +236.0% |
| SBTX | ARS Pharmaceuticals, Inc. | $13,443,222 | +2.9% | 2,006,451 | 0.0% | 0.08% | +9.9% | |
| SANA | Sana Biotechnology, Inc. | $11,920,000 | +82.3% | 2,000,000 | 0.0% | 0.07% | +91.7% | |
| DAWN | New | Day One Biopharmaceuticals, Inc. | $11,940,000 | – | 1,000,000 | +100.0% | 0.07% | – |
| COGT | New | Cogent Biosciences, Inc. | $11,598,464 | – | 979,600 | +100.0% | 0.07% | – |
| PNT | POINT Biopharma Global Inc. | $10,592,073 | +24.6% | 1,169,103 | 0.0% | 0.06% | +32.6% | |
| ADAP | Buy | Adaptimmune Therapeutics plcsponsored adr | $10,146,586 | -5.3% | 10,969,282 | +11.6% | 0.06% | +1.7% |
| NVTA | Invitae Corporation | $10,035,648 | -16.3% | 8,881,104 | 0.0% | 0.06% | -10.8% | |
| New | Verastem, Inc. | $9,943,448 | – | 1,336,485 | +100.0% | 0.06% | – | |
| GERN | Geron Corporation | $9,826,529 | +47.9% | 3,061,224 | 0.0% | 0.06% | +58.3% | |
| HRTX | Heron Therapeutics, Inc. | $9,432,746 | -23.2% | 8,131,678 | 0.0% | 0.06% | -17.9% | |
| ATHA | Buy | Athira Pharma, Inc. | $9,303,731 | +58.3% | 3,153,807 | +34.2% | 0.05% | +68.8% |
| RNA | Sell | Avidity Biosciences, Inc. | $8,865,912 | -42.5% | 799,451 | -20.4% | 0.05% | -39.3% |
| BLUE | bluebird bio, Inc. | $8,224,062 | +3.5% | 2,499,715 | 0.0% | 0.05% | +11.6% | |
| FATE | Fate Therapeutics, Inc. | $7,957,373 | -16.5% | 1,671,717 | 0.0% | 0.05% | -11.5% | |
| ALLO | Allogene Therapeutics, Inc. | $7,837,198 | +0.6% | 1,576,901 | 0.0% | 0.04% | +7.1% | |
| OPT | Opthea Limitedsponsored ads | $7,535,895 | -29.1% | 2,691,391 | 0.0% | 0.04% | -24.1% | |
| INSM | Insmed Incorporated | $7,237,300 | +23.8% | 343,000 | 0.0% | 0.04% | +31.2% | |
| TScan Therapeutics, Inc. | $6,961,980 | +19.0% | 2,784,792 | 0.0% | 0.04% | +25.0% | ||
| Aadi Bioscience, Inc. | $6,771,108 | -5.5% | 989,928 | 0.0% | 0.04% | 0.0% | ||
| ALEC | Alector, Inc. | $5,798,755 | -2.9% | 964,851 | 0.0% | 0.03% | +6.2% | |
| Sell | Sera Prognostics, Inc. | $5,856,648 | -14.5% | 1,777,435 | -0.6% | 0.03% | -8.1% | |
| CMPX | Compass Therapeutics, Inc. | $4,953,263 | -2.8% | 1,557,630 | 0.0% | 0.03% | +3.6% | |
| NTRA | Natera, Inc. | $4,866,000 | -12.4% | 100,000 | 0.0% | 0.03% | -6.7% | |
| MGNX | MacroGenics, Inc. | $4,775,298 | -25.4% | 892,579 | 0.0% | 0.03% | -20.0% | |
| MREO | New | Mereo BioPharma Group PLCsponsored ads | $4,692,572 | – | 3,554,979 | +100.0% | 0.03% | – |
| ARAV | Aravive, Inc. | $4,109,142 | -37.0% | 3,261,224 | 0.0% | 0.02% | -31.4% | |
| HOOK | Buy | HOOKIPA Pharma Inc. | $3,894,471 | +52.2% | 4,425,535 | +27.3% | 0.02% | +64.3% |
| AFMD | Affimed N.V. | $3,946,224 | -19.8% | 6,596,830 | 0.0% | 0.02% | -14.8% | |
| EWTX | Edgewise Therapeutics, Inc. | $3,875,000 | +16.2% | 500,000 | 0.0% | 0.02% | +22.2% | |
| GRCL | New | Gracell Biotechnologies Inc.sponsored ads | $3,810,000 | – | 1,000,000 | +100.0% | 0.02% | – |
| IPSC | Century Therapeutics, Inc. | $3,631,914 | -8.9% | 1,149,340 | 0.0% | 0.02% | -4.5% | |
| MRSN | Sell | Mersana Therapeutics, Inc. | $3,573,318 | -53.9% | 1,086,115 | -42.4% | 0.02% | -50.0% |
| New | Leap Therapeutics, Inc. | $3,668,908 | – | 1,172,175 | +100.0% | 0.02% | – | |
| New | Talis Biomedical Corporation | $3,659,921 | – | 7,624,835 | +100.0% | 0.02% | – | |
| BCEL | Atreca, Inc. | $3,462,105 | -14.0% | 3,532,760 | 0.0% | 0.02% | -9.1% | |
| DSGN | Sell | Design Therapeutics, Inc. | $3,150,000 | -12.9% | 500,000 | -20.2% | 0.02% | -10.0% |
| NLTX | Neoleukin Therapeutics, Inc. | $3,172,044 | +18.6% | 3,821,740 | 0.0% | 0.02% | +20.0% | |
| XNCR | Xencor, Inc. | $3,074,481 | -10.5% | 123,127 | 0.0% | 0.02% | -5.3% | |
| TIL | Instil Bio, Inc. | $2,905,858 | -16.6% | 5,273,789 | 0.0% | 0.02% | -10.5% | |
| Tango Therapeutics, Inc. | $2,490,000 | -15.9% | 750,000 | 0.0% | 0.01% | -12.5% | ||
| VERA | Sell | Vera Therapeutics, Inc.cl a | $2,350,747 | -9.1% | 146,464 | -56.1% | 0.01% | 0.0% |
| ACHL | Sell | Achilles Therapeutics plcsponsored ads | $2,417,017 | -2.6% | 2,557,149 | -1.3% | 0.01% | +7.7% |
| PCVX | Vaxcyte, Inc. | $2,441,317 | +33.2% | 48,885 | 0.0% | 0.01% | +40.0% | |
| PRAX | Praxis Precision Medicines, Inc. | $2,161,902 | +42.2% | 1,879,915 | 0.0% | 0.01% | +62.5% | |
| ALGS | Aligos Therapeutics, Inc. | $2,016,184 | +11.1% | 2,076,400 | 0.0% | 0.01% | +20.0% | |
| PMVP | PMV Pharmaceuticals, Inc. | $2,015,870 | +31.2% | 322,024 | 0.0% | 0.01% | +50.0% | |
| ITOS | iTeos Therapeutics, Inc. | $1,990,581 | -2.7% | 150,346 | 0.0% | 0.01% | +9.1% | |
| VOR | Vor Biopharma Inc. | $1,958,590 | -42.6% | 633,848 | 0.0% | 0.01% | -42.1% | |
| Buy | Kala Pharmaceuticals, Inc. | $1,695,548 | +46.7% | 116,213 | +51.3% | 0.01% | +66.7% | |
| ISR | New | Perspective Therapeutics, Inc. | $1,549,283 | – | 2,319,286 | +100.0% | 0.01% | – |
| AGLE | Aeglea BioTherapeutics, Inc. | $1,536,253 | +55.3% | 3,410,106 | 0.0% | 0.01% | +80.0% | |
| FGEN | Sell | FibroGen, Inc. | $642,827 | -98.7% | 238,084 | -91.0% | 0.00% | -98.5% |
| NKTX | Sell | Nkarta, Inc. | $594,211 | -58.2% | 271,329 | -32.2% | 0.00% | -62.5% |
| TARA | Protara Therapeutics, Inc. | $477,214 | -23.6% | 199,671 | 0.0% | 0.00% | 0.0% | |
| VINC | Sell | Vincerx Pharma, Inc. | $293,253 | +16.8% | 225,579 | -6.5% | 0.00% | +100.0% |
| GTH | Genetron Holdings Limitedads | $423,480 | -11.4% | 455,306 | 0.0% | 0.00% | -33.3% | |
| FHTX | Foghorn Therapeutics Inc. | $316,990 | +13.5% | 45,027 | 0.0% | 0.00% | 0.0% | |
| Surrozen, Inc.w exp 8/11/2026 | $46,000 | -44.8% | 833,333 | 0.0% | 0.00% | – | ||
| Exit | Bellicum Pharmaceuticals, Inc. | $0 | – | -249,123 | -100.0% | 0.00% | – | |
| TCRR | Exit | TCR2 Therapeutics Inc. | $0 | – | -753,064 | -100.0% | -0.01% | – |
| VERU | Exit | Veru Inc. | $0 | – | -1,609,579 | -100.0% | -0.01% | – |
| ATRA | Exit | Atara Biotherapeutics, Inc. | $0 | – | -744,186 | -100.0% | -0.01% | – |
| LPTX | Exit | Leap Therapeutics, Inc. | $0 | – | -7,425,570 | -100.0% | -0.01% | – |
| TLIS | Exit | Talis Biomedical Corporation | $0 | – | -7,624,835 | -100.0% | -0.02% | – |
| VSTM | Exit | Verastem, Inc. | $0 | – | -25,521,447 | -100.0% | -0.06% | – |
| BPMC | Exit | Blueprint Medicines Corporation | $0 | – | -333,665 | -100.0% | -0.08% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 41 | Q2 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 41 | Q2 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 41 | Q2 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 41 | Q2 2023 | 1.7% |
| Cerus Corporation | 41 | Q2 2023 | 0.9% |
| Insmed Incorporated | 41 | Q2 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 40 | Q2 2023 | 1.8% |
| Bluebird Bio Inc. | 40 | Q2 2023 | 0.3% |
| Heron Therapeutics, Inc. | 38 | Q2 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| IGM Biosciences, Inc. | June 28, 2023 | 3,277,567 | 10.0% |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| Prelude Therapeutics Inc | May 24, 2023 | 10,219,080 | 19.5% |
| BeiGene, Ltd. | May 05, 2023 | 152,522,377 | 11.2% |
| BELLICUM PHARMACEUTICALS, INC | May 05, 2023 | 2,197,919 | 20.0% |
| Seagen Inc. | May 03, 2023 | 44,617,299 | 23.8% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2023-08-17 |
| SC 13D/A | 2023-08-17 |
| 13F-HR | 2023-08-14 |
| SC 13G/A | 2023-08-10 |
| SC 13G/A | 2023-08-10 |
| SC 13D/A | 2023-08-08 |
| SC 13D/A | 2023-07-19 |
| 4 | 2023-07-05 |
| 4 | 2023-07-05 |
| 4 | 2023-07-05 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.